Literature DB >> 23095407

Advances in continuous renal replacement therapy: citrate anticoagulation update.

Ashita Tolwani1, Keith M Wille.   

Abstract

Because of the potential side effects of heparin, methods of regional citrate anticoagulation (RCA) for continuous renal replacement therapy (CRRT) have been gaining wider acceptance with the development of simplified and safer protocols. Advantages of RCA include the avoidance of systemic anticoagulation and heparin-induced thrombocytopenia. The disadvantage is that citrate can add complexity and labor intensity to CRRT. Frequent monitoring of electrolytes, ionized calcium, and acid-base status is required, due to the potential for hypernatremia, metabolic alkalosis, and systemic ionized hypocalcemia. If properly monitored, complications associated with RCA are uncommon. A variety of methods of delivering RCA are described in the literature. Overall, studies of RCA, as compared to unfractionated heparin, report better filter survival times and less bleeding. In this section, we summarize the characteristics of citrate as an anticoagulant and provide an update of citrate use in CRRT.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23095407     DOI: 10.1159/000342378

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  18 in total

1.  Managing Issues in Dialysis for the Patient with AKI.

Authors:  Eric Judd; Ashita Tolwani
Journal:  Clin J Am Soc Nephrol       Date:  2017-06-21       Impact factor: 8.237

Review 2.  Continuous Renal Replacement Therapy: Who, When, Why, and How.

Authors:  Srijan Tandukar; Paul M Palevsky
Journal:  Chest       Date:  2018-09-25       Impact factor: 9.410

3.  Treatment dose and the elimination rates of electrolytes, vitamins, and trace elements during continuous veno-venous hemodialysis (CVVHD).

Authors:  Thomas Datzmann; Karl Träger; Bernd Schröppel; Helmut Reinelt; Philipp von Freyberg
Journal:  Int Urol Nephrol       Date:  2018-04-02       Impact factor: 2.370

4.  Citrate modulates lipopolysaccharide-induced monocyte inflammatory responses.

Authors:  M J Ashbrook; K L McDonough; J J Pituch; P L Christopherson; T T Cornell; D T Selewski; T P Shanley; N B Blatt
Journal:  Clin Exp Immunol       Date:  2015-04-19       Impact factor: 4.330

Review 5.  How To Prescribe And Troubleshoot Continuous Renal Replacement Therapy: A Case-Based Review.

Authors:  Javier A Neyra; Lenar Yessayan; Melissa L Thompson Bastin; Keith M Wille; Ashita J Tolwani
Journal:  Kidney360       Date:  2020-12-14

6.  Continuous Renal Replacement Therapy in Pediatric Patients With Acute Kidney Injury After Liver Transplantation.

Authors:  Yan Sun; Sinan Gao; Xingqiang Wang; Lixin Yu; Min Xu; Wei Gao; Chao Sun; Bing Wang
Journal:  Front Pediatr       Date:  2022-06-22       Impact factor: 3.569

Review 7.  Regional citrate anticoagulation for RRTs in critically ill patients with AKI.

Authors:  Santo Morabito; Valentina Pistolesi; Luigi Tritapepe; Enrico Fiaccadori
Journal:  Clin J Am Soc Nephrol       Date:  2014-07-03       Impact factor: 8.237

8.  Chemical and microbiological stability, anticoagulant efficacy and toxicity of 35 and 90 mM trisodium citrate solutions stored in plastic syringes.

Authors:  Paola Milla; Maria Luisa Viterbo; Sabino Mosca; Silvia Arpicco
Journal:  Eur J Hosp Pharm       Date:  2017-01-13

9.  Electrolyte monitoring during regional citrate anticoagulation in continuous renal replacement therapy.

Authors:  C Warnar; E Faber; P A Katinakis; T Schermer; P E Spronk
Journal:  J Clin Monit Comput       Date:  2021-05-15       Impact factor: 1.977

10.  Regional citrate anticoagulation "non-shock" protocol with pre-calculated flow settings for patients with at least 6 L/hour liver citrate clearance.

Authors:  Lenar Yessayan; Ryann Sohaney; Vidhit Puri; Benjamin Wagner; Amy Riddle; Sharon Dickinson; Lena Napolitano; Michael Heung; David Humes; Balazs Szamosfalvi
Journal:  BMC Nephrol       Date:  2021-07-02       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.